Medical devices, healthcare technology and the business of care
PMA approval · P070001

PRODISC TM-C TOTAL DISC REPLACEMENT

Centinel Spine, LLC · Decision date Dec 17, 2007

MEDTECHLEDGER EXPLANATIONP070001

What did the FDA approve?

FDA approved the ProDisc-C Total Disc Replacement on December 17, 2007, for skeletally mature patients requiring reconstruction of the disc from C3-C7 after single-level discectomy for intractable symptomatic cervical disc disease. The device is implanted through an open anterior approach. Patients must have failed at least six weeks of non-operative treatment before implantation.

Symptomatic cervical disc disease is defined in the approval as neck or arm (radicular) pain and/or a functional/neurological deficit with at least one imaging-confirmed condition: herniated nucleus pulposus, spondylosis defined by osteophytes, and/or loss of disc height. The statement reports the approved indication and conditions; it does not independently establish safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR THE PRODISC-C TOTAL DISC REPLACEMENT. THE DEVICE IS INDICATED FOR SKELETALLY MATURE PATIENTS FOR RECONSTRUCTION OF THE DISC FROM C3-C7 FOLLOWING SINGLE-LEVEL DISCECTOMY FOR INTRACTABLE SYMPTOMATIC CERVICAL DISC DISEASE (SCDD). SYMPTOMATIC CERVICAL DISC DISEASE IS DEFINED AS NECK OR ARM (RADICULAR) PAIN AND/OR A FUNCTIONAL/NEUROLOGICAL DEFICIT WITH AT LEAST ONE OF THE FOLLOWING CONDITIONS CONFIRMED BY IMAGING (CT, MRI, OR X-RAYS): HERNIATED NUCLEUS PULPOSUS, SPONDYLOSIS (DEFINED BY THE PRESENCE OF OSTEOPHYTES), AND/OR LOSS OF DISC HEIGHT. THE PRODISC-C TOTAL DISC REPLACEMENT IS IMPLANTED VIA AN OPEN ANTERIOR APPROACH. PATIENTS RECEIVING THE PRODISC-C TOTAL DISC REPLACEMENT SHOULD HAVE FAILED AT LEAST SIX WEEKS OF NON-OPERATIVE TREATMENT PRIOR TO IMPLANTATION OF THE PRODISC-C TOTAL DISC REPLACEMENT.
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Dec 17, 2007

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P070001
Regulatory pathway
Premarket approval application
Product code
MJO
Decision code
APPR
Decision date
Dec 17, 2007
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, intervertebral disc.

Product code
MJO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P070001 received

    Application receipt date recorded by FDA.

  2. P070001 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P070001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070001

Product / regulatory recordCompanyPathwayDecision dateSource
prodisc C NovaP070001/S031
Centinel Spine, LLCPMA supplementSep 9, 2026FDA

Explore the linked device profile

Other records with product code MJO

Product / regulatory recordCompanyPathwayDecision dateSource
Spineart USA, Inc.PMA supplementSep 22, 2026FDA
Synergy DiscP250028/S003
Synergy Spine Solutions, Inc.PMA supplementSep 17, 2026FDA
Highridge Medical, LLCPMA supplementSep 16, 2026FDA
Highridge Medical, LLCPMA supplementSep 16, 2026FDA
Spineart USA, Inc.PMA approvalAug 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Centinel Spine, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
900 Airport Rd., Suite 3b, West Chester, PA, 19380

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records